CTi Biopharma — Investor Presentation (January 2015)
33 slides from CTi Biopharma's investor presentation, Jan 13, 2015
Slide 1: Corporate Presentation
Exhibit 99.1 Conquering Cancer. It’s in our blood.™ CORPORATE PRESENTATION San Francisco – January 13, 2015 © Copyright 2015 CTI BioPharma Corp. All rights reserved.
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a
Slide 3: Accomplishments in 2014
Accomplishments in 2014 Building Shareholder Value Entered into a $133 million* collaboration for PIXUVRI to expand commercial potential of product Advanced pacritinib Phase 3 program in myelofibrosis; completed 1 st Phase 3 trial and received $20mm from Baxter Reported preclinical data highlighting
Slide 4: 2015 Key Objectives
2015 Key Objectives Pacritinib • Report top-line results from PERSIST-1 Phase 3 MF trial late 1Q-2015 • Complete enrollment of PERSIST-2 mid-2015 • Begin rolling submission of NDA late 2015 • Advance development program in other hematologic malignancies PIXUVRI • Generate sufficient E.U. sales to ac
Slide 5: Preliminary 2015 Revenue Projections
Preliminary 2015 Revenue Projections $80 Preliminary Year-Over-Year Revenue Comparison* $70 $60 Projected range of $50 $55mm - $72mm $40 $30 $20 $10 $- 2013 Actual 2014 E* 2015E * *This estimate is unaudited, preliminary and may change. CTI BioPharma and its auditors have not completed our normal an
Slide 6: Strategic Approach to Commercialize Globally
Strategic Approach to Commercialize Globally U.S. Europe ROW Develop Full Core Markets Collaboration [North Western Europe] Commercial For PIXUVRI, pacritinib Capabilities Commercializing PIX and tosedostat and future products For pacritinib*; PIXUVRI • SERVIER for PIXUVRI and tosedostat • Cost-effe
Slide 7: Building a Successful Oncology Business
Building a Successful Oncology Business Therapeutic Focus: Novel Targeted Therapies Blood-Related Cancers MPNs Leukemia Lymphoma MF and PV AML and MDS NHL and CLL 7
Slide 8: CTI BioPharma Opportunity
CTI BioPharma Opportunity nd 1st approved therapy in the E.U. for relapsed aggressive B-cell NHL beyond 2 line; ongoing confirmatory Phase 3 trial Targeting cash flow positive operations in 2015 Collaboration with SERVIER of up to ~$133* million Fast Track designated product candidate Phase 3 top-li
Slide 9: Pacritinib
Pacritinib
Slide 10: Myelofibrosis: A Chronic Disease
Myelofibrosis: A Chronic Disease • Malignant bone marrow disorder triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood cells prompting the spleen and liver to compensate • Symptoms include: enlargement of the spleen, anemia, thrombocytopenia, extreme
Slide 11: Pacritinib: Market Opportunity in MF
Pacritinib: Market Opportunity in MF • Approved drug Jakafi ®/Jakavi® (ruxolitinib) Total 2014 U.S. net sales estimated at $350-360mm 1; $600mm - $1bn 2015 run-rate worldwide • Treatment emergent thrombocytopenia and anemia are limitations of most JAK1/JAK2 inhibitors, including ruxolitinib • Market
Slide 12: Evaluating Pacritinib in All MF Patients
Evaluating Pacritinib in All MF Patients Fast Track Designation; Global Registration Program • PERSIST-1 compares pacritinib to BAT, excludes ruxolitinib All MF • Fully enrolled; Top-line results expected late in 1Q-2015 Patients • Most inclusive randomized Phase 3 study • INT-1, 2 High risk, no res
Slide 13: PERSIST-1 Representative of MF Population
PERSIST-1 Representative of MF Population Distribution (%) Platelets Projected Distribution (%) 1-3 in MF Patients Platelets in MF Patient in PERSIST-1 4 16 10 19 11 63 15 54 12 >150,000/µL 100- 150,000/µL >150,000/µL 100-150,000/µL 50-100,000/µL <50,000/µL 50-100,000/µL <50,000/µL The duration of t
Slide 14: PERSIST Program Phase 3 Trial - Timeline
PERSIST Program Phase 3 Trial - Timeline July 2014: PERSIST-1 enrollment complete; March 2014: $20mm Open milestone enrollment for PERSIST-2 March 2015: Expect to report PERSIST-1 top-line November 2013: results June 2012: BAXTER Acquired collaboration pacritinib from October 2013: 460mm upfront S*B
Slide 15: Pacritinib: Unique Kinome Profile
Pacritinib: Unique Kinome Profile1 • Pacritinib is an oral multikinase inhibitor with specificity for kinases in several unrelated families • The inhibition of IRAK1 and c-fms (CSF1R) may contribute to its anti-inflammatory activity and early onset of symptomatic benefit in MF • Suggests its potenti
Slide 16: Pacritinib: AML Target Indication
Pacritinib: AML Target Indication • Able to target multiple pathways, including suppression of microenvironmental tumor interactions that are key to overcoming Signaling pathways initiated by FLT3 longer-term drug resistance in this disease ligand activation of the FLT3 receptor • FLT3 strong progno
Slide 17: Pacritinib: Key Takeaways
Pacritinib: Key Takeaways • Oral JAK2/FLT3 inhibitor that lacks treatment emergent myelosuppression associated with marketed JAK1/JAK2 agent - Potential to demonstrate superior disease and symptom control over titrated doses of ruxolitinib - May be used in combination regimens w/o overlapping myelos
Slide 18: Pacritinib: Collaboration with Baxter
Pacritinib: Collaboration with Baxter Announced November 2013 • CTI and BAXTER: Joint commercialization, profit split in U.S. • BAXTER: Exclusive rights to commercialize in all indications outside U.S., BAXTER generally responsible for 75% of global development Summary of Financial Terms • Potential
Slide 19: PIXUVRI
PIXUVRI®
Slide 20: PIXUVRI: Fulfilling An Unmet Clinical Need
PIXUVRI: Fulfilling An Unmet Clinical Need st nd rd 1 LINE 2 LINE 3 LINE+ • Typically • Intensive (toxic) • Palliative care anthracycline- non-anthracycline (symptom control) based treatment based salvage or clinical trials R-CHOP therapy (R-DHAP), +/- ASCT • Curative in 50% - 1 55% of patients • Al
Slide 21: PIXUVRI: Overview
PIXUVRI: Overview One of the most active agents in R/R aggressive B-cell NHL where there was no standard therapy • Novel MOA: DNA alkylation/mitotic instability PIXUVRI appears to be impairing chromosomal segregation during mitosis, thereby generating loss of genetic material in daughter cells, an a
Slide 22: PIXUVRI: Demonstrated Benefit in Phase 3
PIXUVRI: Demonstrated Benefit in Phase 3 PIX301* - Only randomized controlled Phase 3 trial in 3 rd-line aggressive B-cell NHL (n=140 patients) Patient Population • Heavily pre-treated patients; median of 3 prior treatments • Median age was 60 years rd ITT Population 3 /4 th Line B-cell Results PIXU
Slide 23: PIXUVRI: Approved as Monotherapy by EMA
PIXUVRI: Approved as Monotherapy by EMA st • 1 and only approved monotherapy in the rd th E.U. for aggressive B-cell NHL 3 /4 line nd rd nd • 2 salvage (3 line) = 2 chance at potentially curative ASCT* • Durable rd th remissions and disease control (3 /4 line) in non-SCT eligible • Label expansion s
Slide 24: PIXUVRI: PIX306 Study
PIXUVRI: PIX306 Study Post-marketing Commitment Phase 3 Study Eligibility Criteria Pixantrone* Primary Endpoint 1:1 Rituximab PFS Relapse after CHOP-R therapy or an equivalent Randomization regimen and are Secondary n = ~220 Gemcitabine* Endpoints ineligible for stem cell transplant Rituximab CR ORR
Slide 25: PIXUVRI EU Sales Since Launch
PIXUVRI EU Sales Since Launch Net PIXUVRI Sales by Quarter ($ in millions) 2.5 2 1.5 1 0.5 0 Q2 Q3 Q4 Q1 Q2 Q3 2013 2014 Focus on Reimbursement Germany UK Netherlands 25
Slide 26: PIXUVRI: Maximizing the European Commercial Opportunity
PIXUVRI: Maximizing the European Commercial Opportunity • Exclusive license and collaboration agreement with SERVIER to develop and expand commercial reach 10+ Countries • Reimbursed in Austria, England/Wales, Germany, ~5,000 Netherlands Current eligible patients • Standard of care per treatment gui
Slide 27: PIXUVRI Collaboration with SERVIER
PIXUVRI Collaboration with SERVIER Announced September 2014 • Exclusive license and collaboration agreement to develop and expand commercial reach of PIXUVRI • CTI retains 100% U.S. rights, continues its commercial presence in UK, Germany/Austria, Nordics, and via distribution partners in Turkey, Is
Slide 28: Continued Growth Expected in aNHL in 2015
Continued Growth Expected in aNHL in 2015 • Continue to build awareness and educate HCPs • Expand field force; medical science liaisons key • Growing body of evidence on potential for combination studies • Limited near-term competition expected 28
Slide 29: Tosedostat
Tosedostat
Slide 30: Tosedostat
Tosedostat Novel Treatment for Blood-Related Cancers: MDS & AML • Oral, once-daily, aminopeptidase inhibitor interferes with protein recycling, prevents breakdown of peptides into amino acids necessary for tumor cell survival • Synergy with targeted agents (HMA, proteosome inhibitors) or chemotherap
Slide 31: Financial Overview
Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Market Capitalization* ~$417mm Shares Outstanding** ~177mm Cash as of November 30, 2014 $82mm Debt $20mm *As of January 9, 2015 stock price of $2.36 per share. ** As of December 15, 2014. 31
Slide 32: Why Invest in CTI BioPharma?
Why Invest in CTI BioPharma? Biopharmaceutical company with a marketed oncology drug in the E.U. Strategic partner provides validation, financial resources and commercial support for high-potential JAK2/FLT3 inhibitor Phase 3 program Building value through development of late-stage pipeline, with em
Slide 33: Thank You!
THANK YOU! Ctl BIOPHARMA NASDAQ & MTA: CTIC